Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($0.92), $0.09 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $3.82 million versus the consensus estimate of $928.57 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.